BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Home
/
update
/
details

Ocugen’s Chief Scientific Officer to Present Gene Therapy Innovations at Upcoming Conference

NextEdge Admin

07 Sep 2024

2 min 10 sec

Ocugen, Inc. has announced that its Chief Scientific Officer, Dr. Arun Upadhyay, will be a featured speaker at the 5th Annual Gene Therapy for Ophthalmic Disorders conference, taking place from September 10-12, 2024, in Boston, Massachusetts. This prominent event gathers professionals from the biotech and pharmaceutical industries to discuss cutting-edge innovations in gene therapy for eye diseases.

On September 10, Dr. Upadhyay will lead a workshop addressing the complexities of regulatory pathways for ophthalmic gene therapies. This session will be instrumental in helping attendees understand the approval processes required to bring new therapies to market. On September 12, he will present Ocugen’s latest advancements in gene therapy, specifically focusing on the company’s modifier gene therapy platform and its clinical progress for ophthalmic disorders.

"There is tremendous potential for gene therapy to treat both rare retinal diseases and more widespread ophthalmic conditions," Dr. Upadhyay commented, emphasizing the importance of continued research and collaboration in advancing the field. His involvement highlights Ocugen’s dedication to pioneering treatment options for eye disorders.

The conference will feature over 70 industry leaders, covering breakthroughs in vector engineering, delivery techniques, and clinical trial strategies. Attendees will gain valuable insights into optimizing gene therapy approaches for retinal diseases, making the event a must-attend for those invested in the future of ocular health and gene therapy.